PubMed Health⌕ Search

Biomedical subjects

S Finnegan

Publications and source records attributed to S Finnegan.

9 recordsLinked to original sources
PubMed1995

Anaerobic treatment of sulphate-containing waste streams.

Sulphate-containing wastewaters from the paper and board industry, molasses-based fermentation industries and edible oil refineries present difficulties during anaerobic treatment, leading to problems of toxicity, reduction in methane yield, odour and corrosion. The microbiology and biochemistry of dissimilatory sulphate reduction are reviewed in order to illustrate the potential competition between sulphate reducers and other anaerobes involved in the sequential anaerobic mineralisation process. The theoretical considerations which influence the outcome of competition between sulphate reducers and fermentative, syntrophic, homoacetogenic and methanogenic bacteria are discussed. The actual outcome, under the varying influent organic composition and strength and sulfate concentrations which prevail during digestion of industrial wastewaters, may be quite different to that predicted by thermodynamic or kinetic considerations. The factors governing competitive interactions between SRB and other anaerobes involved in methanogenesis is discussed in the context of literature data on sulphate wastewater treatment and with particular reference to laboratory and full-scale digestion of citric acid production wastewater.

Biodegradation, Environmental↗
PubMed1991

Spectrum of intestinal failure in a specialised unit.

300 consecutive admissions over 7 years to a purpose-built intestinal failure unit are reviewed. The commonest underlying condition was Crohn's disease (42%), and the commonest complication precipitating admission was intestinal fistula (42%). Total parenteral nutrition was used in 85% and surgery in 50%. A multidisciplinary approach to management gave a high success rate--90% of patients were discharged from hospital, although nearly 25% needed home parental nutrition. These results suggest that chronic intestinal failure should be managed in specialised units in the same manner as other types of organ failure.

Adolescent↗
PubMed1990

Octreotide and gastrointestinal fistulae.

The place of somatostatin and its analogues in the management of gastrointestinal fistulae is reviewed, drawing attention to the difficulty of assessing treatments that influence spontaneous closure. Sixteen patients with gastric, small bowel, and pancreatic fistulae were randomized to receive octreotide injections (100 micrograms t.i.d.) or placebo for 12 days. Spontaneous fistula closure occurred in 7 at a mean of 37 days after entering the trial. A second study is underway with greater patient numbers recruited from peripheral hospitals and with an increased period of octreotide medication (21 days).

Adult↗
PubMedDate not supplied

Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study.

Nineteen patients with postoperative enterocutaneous fistulae were randomised, in a double blind fashion, to receive either 12 days of octreotide (100 micrograms tds) by subcutaneous injection or 12 days of placebo injections. Fistula output for 7 days before and during all 12 days of treatment was recorded for each patient. Fistula losses before entering the trial were similar for both the placebo group (n = 8; range of daily medians: 202 mls to 400 mls) and the group of patients randomised to receive octreotide (n = 11; range of daily medians: 252 mls to 550 mls). There was no significant difference in fistula output between the two groups of patients while receiving either 12 days of placebo injections or 12 days of subcutaneous octreotide therapy. Fistula closure, defined as no fistula output for 2 successive days during the 12 days "therapy" period, was seen in only 1 patient given octreotide and in 3 patients given the placebo. In a double blind prospective study of 19 patients with enterocutaneous fistulae, octreotide therapy was neither associated with a significant reduction in fistula losses nor an increased rate of spontaneous fistula closure.

Adult↗